These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 12215250)

  • 1. What does my doctor think? Preferences for knowing the doctor's opinion among women considering clinical testing for BRCA1/2 mutations.
    Armstrong K; Stopfer J; Calzone K; Fitzgerald G; Coyne J; Weber B
    Genet Test; 2002; 6(2):115-8. PubMed ID: 12215250
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors associated with decisions about clinical BRCA1/2 testing.
    Armstrong K; Calzone K; Stopfer J; Fitzgerald G; Coyne J; Weber B
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1251-4. PubMed ID: 11097234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.
    Moyer VA;
    Ann Intern Med; 2014 Feb; 160(4):271-81. PubMed ID: 24366376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.
    Hartenbach EM; Becker JM; Grosen EA; Bailey HH; Petereit DG; Laxova R; Schink JC
    Genet Test; 2002; 6(2):75-8. PubMed ID: 12229876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which factors predict proposal and uptake of psychological counselling after BRCA1/2 test result disclosure?
    Maheu C; Bouhnik AD; Nogues C; Mouret-Fourme E; Stoppa-Lyonnet D; Lasset C; Berthet P; Fricker JP; Caron O; Luporsi E; Gladieff L; Julian-Reynier C
    Psychooncology; 2014 Apr; 23(4):420-7. PubMed ID: 24127257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interest in BRCA1/2 testing in a primary care population.
    Armstrong K; Weber B; Ubel PA; Guerra C; Schwartz JS
    Prev Med; 2002 Jun; 34(6):590-5. PubMed ID: 12052018
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.
    Rebbeck TR; Lynch HT; Neuhausen SL; Narod SA; Van't Veer L; Garber JE; Evans G; Isaacs C; Daly MB; Matloff E; Olopade OI; Weber BL;
    N Engl J Med; 2002 May; 346(21):1616-22. PubMed ID: 12023993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early adoption of BRCA1/2 testing: who and why.
    Armstrong K; Weiner J; Weber B; Asch DA
    Genet Med; 2003; 5(2):92-8. PubMed ID: 12644778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Too much, too soon? Patients and health professionals' views concerning the impact of genetic testing at the time of breast cancer diagnosis in women under the age of 40.
    Ardern-Jones A; Kenen R; Eeles R
    Eur J Cancer Care (Engl); 2005 Jul; 14(3):272-81. PubMed ID: 15952973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health care provider recommendations for reducing cancer risks among women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Kim-Sing C; Ghadirian P; Sun P; Narod SA
    Clin Genet; 2014 Jan; 85(1):21-30. PubMed ID: 23859469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study.
    Domchek SM; Friebel TM; Neuhausen SL; Wagner T; Evans G; Isaacs C; Garber JE; Daly MB; Eeles R; Matloff E; Tomlinson GE; Van't Veer L; Lynch HT; Olopade OI; Weber BL; Rebbeck TR
    Lancet Oncol; 2006 Mar; 7(3):223-9. PubMed ID: 16510331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
    Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 24366402
    [No Abstract]   [Full Text] [Related]  

  • 19. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
    Spannuth WA; Thaker PH; Sood AK
    Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.